EUVIMEDEUVIMED entdecken
Open Access

Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy

M Herman Chui iD, David N Brown, Arnaud Da Cruz Paula, Edaise M da Silva, Amir Momeni-Boroujeni, Jorge S Reis-Filho iD, Yanming Zhang, Vicky Makker, Lora Hedrick Ellenson, Britta Weigelt iD

The Journal of Pathology · 2024

DOI: 10.1002/path.6230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2024. Verfasst von M Herman Chui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Endometrial Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab has demonstrated clinical efficacy in the treatment of HER2‐positive serous endometrial cancer (EC), which led to its incorporation into standard‐of‐care management of this aggressive disease. Acquired resistance remains an important challenge, however, and its underlying mechanisms in EC are unknown. To define the molecular changes that occur in response to anti‐HER2 therapy in EC, targeted next‐generation sequencing (NGS), HER2 immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) were performed on pre‐ and post‐treatment tumour samples from 14 patients with EC treated with trastuzumab or trastuzumab emtansine. Recurrent tumours after anti‐HER2 therapy acquired additional genetic alterations compared with matched pre‐treatment ECs and frequently showed decreased HER2 protein expression by IHC (7/14, 50%). Complete/near‐complete absence of HER2 protein expression (score 0/1+) observed post‐treatment (4/14, 29%) was associated with retained HER2 gene amplification ( n = 3) or copy number neutral status ( n = 1). Whole‐exome sequencing performed on primary and recurrent tumours from the latter case, which exhibited genetic heterogeneity of HER2 amplification in the primary tumour, revealed selection of an early HER2 ‐non‐amplified clone following therapy. Our findings demonstrate that loss of target expression, by selection of HER2 ‐non‐amplified clones or, more commonly, by downregulation of expression, may constitute a mechanism of resistance to anti‐HER2 therapy in HER2‐positive EC. © 2023 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesEndometrial NeoplasmsFemaleHumansIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalTrastuzumabGene Amplification

Stichwörter der Autor:innen

HER2drug resistancehigh-grade endometrial cancerintratumour heterogeneitytargeted therapytrastuzumabuterine serous cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumab

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: M Herman Chui, Jorge S Reis-Filho, Britta Weigelt

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Cancer Institute
  • Breast Cancer Research Foundation
  • National Institutes of Health

Zitieren

APA

Chui, M. H., Brown, D. N., Da Cruz Paula, A., da Silva, E. M., Momeni-Boroujeni, A., Reis-Filho, J. S., Zhang, Y., Makker, V., Ellenson, L. H., & Weigelt, B. (2024). Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy. The Journal of Pathology. https://doi.org/10.1002/path.6230

Vancouver

Chui MH, Brown DN, Da Cruz Paula A, da Silva EM, Momeni-Boroujeni A, Reis-Filho JS, et al. Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy. The Journal of Pathology. 2024. doi:10.1002/path.6230

BibTeX
@article{Chui2024,
  author = {Chui, M Herman and Brown, David N and Da Cruz Paula, Arnaud and da Silva, Edaise M and Momeni-Boroujeni, Amir and Reis-Filho, Jorge S and Zhang, Yanming and Makker, Vicky and Ellenson, Lora Hedrick and Weigelt, Britta},
  title = {Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6230}
}
Kostenlos starten →